Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NBIX 
Neurocrine Biosciences Inc (NBIX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: NBIX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $168.25
1 Year Target Price $168.25
| 15 | Strong Buy |
| 7 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -0.38% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.07B USD | Price to earnings Ratio 41.97 | 1Y Target Price 168.25 |
Price to earnings Ratio 41.97 | 1Y Target Price 168.25 | ||
Volume (30-day avg) 25 | Beta 0.28 | 52 Weeks Range 84.23 - 154.61 | Updated Date 09/12/2025 |
52 Weeks Range 84.23 - 154.61 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 13.88% | Operating Margin (TTM) 21.18% |
Management Effectiveness
Return on Assets (TTM) 8.67% | Return on Equity (TTM) 13.39% |
Valuation
Trailing PE 41.97 | Forward PE 27.1 | Enterprise Value 13705964836 | Price to Sales(TTM) 5.61 |
Enterprise Value 13705964836 | Price to Sales(TTM) 5.61 | ||
Enterprise Value to Revenue 5.46 | Enterprise Value to EBITDA 24.6 | Shares Outstanding 99181504 | Shares Floating 98005217 |
Shares Outstanding 99181504 | Shares Floating 98005217 | ||
Percent Insiders 1.05 | Percent Institutions 102.06 |
Upturn AI SWOT
Neurocrine Biosciences Inc
Company Overview
History and Background
Neurocrine Biosciences Inc. was founded in 1992. It's a biopharmaceutical company focused on neurological, endocrine, and psychiatric disorders. Initially focused on drug discovery, it shifted to development and commercialization. A significant milestone was the approval and launch of Ingrezza for tardive dyskinesia.
Core Business Areas
- Neurology: Focuses on developing treatments for neurological disorders, with Ingrezza as a primary product for tardive dyskinesia and other movement disorders.
- Endocrinology: Develops treatments for endocrine-related conditions. Has historically included research in areas such as women's health.
- Psychiatry: Focuses on developing treatments for mental health disorders.
Leadership and Structure
Kevin Gorman is the Chief Executive Officer. The company has a typical corporate structure with a board of directors and executive leadership responsible for various functions like research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Ingrezza (valbenazine): Ingrezza is a selective vesicular monoamine transport 2 (VMAT2) inhibitor used for the treatment of tardive dyskinesia (TD) and chorea associated with Huntingtonu2019s disease. Ingrezza holds a significant market share in the TD treatment space. Competitors include Teva Pharmaceutical Industries (Austedo) and possibly future entrants. Ingrezza revenues represent the vast majority of Neurocrine's sales, estimated to be >90%.
- ORILISSA (elagolix): ORILISSA is a gonadotropin-releasing hormone (GnRH) antagonist approved for the treatment of moderate to severe endometriosis pain. Neurocrine Biosciences co-promote ORILISSA with AbbVie, however AbbVie leads the commercialization. Competitors include other hormonal therapies and pain management strategies for endometriosis.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory scrutiny, and patent protection. Demand is driven by aging populations and the prevalence of neurological, endocrine, and psychiatric disorders.
Positioning
Neurocrine Biosciences has established a strong position in the tardive dyskinesia market with Ingrezza. It aims to expand its pipeline to address other underserved neurological and endocrine conditions. Competitive advantages include its expertise in VMAT2 inhibition and its strategic partnerships.
Total Addressable Market (TAM)
The total addressable market for TD is substantial, estimated to be around $4 billion annually. Neurocrine, with Ingrezza, is well-positioned to capture a significant portion of this market. The TAM for endometriosis is also substantial.
Upturn SWOT Analysis
Strengths
- Successful commercialization of Ingrezza
- Strong expertise in VMAT2 inhibition
- Robust pipeline of drug candidates
- Strategic partnerships with larger pharmaceutical companies
Weaknesses
- High dependence on Ingrezza revenue
- Limited product diversification
- Potential for generic competition
- Reliance on AbbVie for ORILISSA co-promotion
Opportunities
- Expanding Ingrezza's indications to other movement disorders
- Developing new therapies for neurological and endocrine conditions
- Acquiring complementary technologies and assets
- Strategic collaborations for pipeline expansion
Threats
- Competition from other pharmaceutical companies
- Patent expiration for Ingrezza
- Regulatory challenges and delays
- Pricing pressures and reimbursement issues
Competitors and Market Share
Key Competitors
- TEVA
Competitive Landscape
Neurocrine Biosciences has a strong competitive position due to Ingrezza's efficacy and market penetration. It faces competition from Teva Pharmaceutical Industries. Neurocrine's competitive advantage lies in the VMAT2 inhibition mechanism and strong sales.
Major Acquisitions
Diurnal Group plc
- Year: 2022
- Acquisition Price (USD millions): 54
- Strategic Rationale: Added expertise in endocrine diseases and a European commercial infrastructure to aid future commercial activities.
Growth Trajectory and Initiatives
Historical Growth: Neurocrine Biosciences Inc. has experienced strong growth, particularly since the launch of Ingrezza.
Future Projections: Analysts project continued revenue growth, driven by increased adoption of Ingrezza and potential new product launches.
Recent Initiatives: Recent initiatives include expanding Ingrezza's indications, advancing pipeline candidates through clinical trials, and seeking strategic collaborations and acquisitions.
Summary
Neurocrine Biosciences is a strong biopharmaceutical company with Ingrezza driving most of its revenue. The company is successfully expanding its presence in the TD market and growing revenues significantly. It faces risks from competition and patent expiration, however, its pipeline and partnerships create potential upside. Growth relies on pipeline products and continued commercial success of Ingrezza.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Neurocrine Biosciences Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
- Market Research Reports
Disclaimers:
The data and analysis provided are for informational purposes only and do not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neurocrine Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 1996-05-23 | CEO & Director Mr. Kyle W. Gano Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1800 | Website https://www.neurocrine.com |
Full time employees 1800 | Website https://www.neurocrine.com | ||
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy and schizophrenia; NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.